Cover Image
市場調查報告書

乾癬 : 開發平台分析

Psoriasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232784
出版日期 內容資訊 英文 699 Pages
訂單完成後即時交付
價格
Back to Top
乾癬 : 開發平台分析 Psoriasis - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 699 Pages
簡介

所謂乾癬是指影響皮膚的慢性自體免疫性疾病,是由於細胞乾燥產生斑塊並引起發炎。症狀有以細胞脫落為首的皮膚腫、發癢、產生燒灼感。相關的危險因子有遺傳、特定藥劑的副作用、壓力、傳染病、環境狀況等。除此之外尚有免疫系統機能異常造成乾癬惡化。可用局部或全身用藥、光線治療等來控制症狀。

本報告提供乾癬的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 乾癬 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8494IDB

Summary

Global Markets Direct's, 'Psoriasis - Pipeline Review, H2 2016', provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Psoriasis
  • The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
  • The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Psoriasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Psoriasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Psoriasis Overview
  • Therapeutics Development
  • Psoriasis - Therapeutics under Development by Companies
  • Psoriasis - Therapeutics under Investigation by Universities/Institutes
  • Psoriasis - Pipeline Products Glance
  • Psoriasis - Products under Development by Companies
  • Psoriasis - Products under Investigation by Universities/Institutes
  • Psoriasis - Companies Involved in Therapeutics Development
  • Psoriasis - Therapeutics Assessment
  • Drug Profiles
  • Psoriasis - Dormant Projects
  • Psoriasis - Discontinued Products
  • Psoriasis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Psoriasis, H2 2016
  • Number of Products under Development for Psoriasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Psoriasis - Pipeline by AbbVie Inc, H2 2016
  • Psoriasis - Pipeline by Abeome Corporation, H2 2016
  • Psoriasis - Pipeline by AbGenomics International, Inc., H2 2016
  • Psoriasis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Psoriasis - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Psoriasis - Pipeline by Affibody AB, H2 2016
  • Psoriasis - Pipeline by Albireo AB, H2 2016
  • Psoriasis - Pipeline by Almirall, S.A., H2 2016
  • Psoriasis - Pipeline by Alteogen Inc., H2 2016
  • Psoriasis - Pipeline by Amgen Inc., H2 2016
  • Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by AnaptysBio, Inc., H2 2016
  • Psoriasis - Pipeline by ApoPharma Inc., H2 2016
  • Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Argos Therapeutics, Inc., H2 2016
  • Psoriasis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016
  • Psoriasis - Pipeline by AstraZeneca Plc, H2 2016
  • Psoriasis - Pipeline by Athenex, Inc., H2 2016
  • Psoriasis - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
  • Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016
  • Psoriasis - Pipeline by Avexxin AS, H2 2016
  • Psoriasis - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
  • Psoriasis - Pipeline by BioApex, s.r.o., H2 2016
  • Psoriasis - Pipeline by BIOCAD, H2 2016
  • Psoriasis - Pipeline by Biocon Limited, H2 2016
  • Psoriasis - Pipeline by BioLingus AG, H2 2016
  • Psoriasis - Pipeline by BioMAS Ltd., H2 2016
  • Psoriasis - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
  • Psoriasis - Pipeline by Bionomics Limited, H2 2016
  • Psoriasis - Pipeline by Bionovis SA, H2 2016
  • Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Psoriasis - Pipeline by Brickell Biotech, Inc., H2 2016
  • Psoriasis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Psoriasis - Pipeline by C4X Discovery Holdings PLC, H2 2016
  • Psoriasis - Pipeline by CalciMedica, Inc., H2 2016
  • Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Psoriasis - Pipeline by Celgene Corporation, H2 2016
  • Psoriasis - Pipeline by Cell Medica Limited, H2 2016
  • Psoriasis - Pipeline by Cellceutix Corporation, H2 2016
  • Psoriasis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Psoriasis - Pipeline by ChironWells GmbH, H2 2016
  • Psoriasis - Pipeline by Clonz Biotech Private Limited, H2 2016
  • Psoriasis - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Psoriasis - Pipeline by Compugen Ltd., H2 2016
  • Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2016
  • Psoriasis - Pipeline by Creabilis SA, H2 2016
  • Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2016
  • Psoriasis - Pipeline by Curapel Limited, H2 2016
  • Psoriasis - Pipeline by Cutanea Life Sciences, Inc., H2 2016
  • Psoriasis - Pipeline by Dermala Inc, H2 2016
  • Psoriasis - Pipeline by Domainex Limited, H2 2016
  • Psoriasis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016
  • Psoriasis - Pipeline by EA Pharma Co Ltd, H2 2016
  • Psoriasis - Pipeline by Eli Lilly and Company, H2 2016
  • Psoriasis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Exicure, Inc., H2 2016
  • Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Psoriasis - Pipeline by Forward Pharma A/S, H2 2016
  • Psoriasis - Pipeline by Gem Pharmaceuticals, LLC, H2 2016
  • Psoriasis - Pipeline by Genentech, Inc., H2 2016
  • Psoriasis - Pipeline by Genor BioPharma Co., Ltd., H2 2016
  • Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Psoriasis - Pipeline by GlycoMar Limited, H2 2016
  • Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
  • Psoriasis - Pipeline by HitGen LTD, H2 2016
  • Psoriasis - Pipeline by Huabo Biopharm Co., Ltd., H2 2016
  • Psoriasis - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Psoriasis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Immune Pharmaceuticals Inc., H2 2016
  • Psoriasis - Pipeline by Immune Response BioPharma, Inc., H2 2016
  • Psoriasis - Pipeline by Immungenetics AG, H2 2016
  • Psoriasis - Pipeline by Innovent Biologics, Inc., H2 2016
  • Psoriasis - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Psoriasis - Pipeline by Johnson & Johnson, H2 2016
  • Psoriasis - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Psoriasis - Pipeline by Lead Pharma Holding B.V., H2 2016
  • Psoriasis - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Psoriasis - Pipeline by LEO Pharma A/S, H2 2016
  • Psoriasis - Pipeline by Lipidor AB, H2 2016
  • Psoriasis - Pipeline by Lupin Limited, H2 2016
  • Psoriasis - Pipeline by Lycera Corp., H2 2016
  • Psoriasis - Pipeline by mAbxience S.A., H2 2016
  • Psoriasis - Pipeline by Maruho Co., Ltd., H2 2016
  • Psoriasis - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Psoriasis - Pipeline by MediGene AG, H2 2016
  • Psoriasis - Pipeline by Merck KGaA, H2 2016
  • Psoriasis - Pipeline by MetrioPharm AG, H2 2016
  • Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Psoriasis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Mycenax Biotech Inc., H2 2016
  • Psoriasis - Pipeline by NeuClone Pty Ltd, H2 2016
  • Psoriasis - Pipeline by Nimbus Therapeutics, LLC, H2 2016
  • Psoriasis - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
  • Psoriasis - Pipeline by Novan, Inc., H2 2016
  • Psoriasis - Pipeline by Novartis AG, H2 2016
  • Psoriasis - Pipeline by Nuevolution AB, H2 2016
  • Psoriasis - Pipeline by Numedii, Inc., H2 2016
  • Psoriasis - Pipeline by Oncobiologics, Inc., H2 2016
  • Psoriasis - Pipeline by OSE Immunotherapeutics, H2 2016
  • Psoriasis - Pipeline by Panacea Biotec Limited, H2 2016
  • Psoriasis - Pipeline by Pfizer Inc., H2 2016
  • Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2016
  • Psoriasis - Pipeline by Pharmedartis GmbH, H2 2016
  • Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2016
  • Psoriasis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016
  • Psoriasis - Pipeline by PinCell srl, H2 2016
  • Psoriasis - Pipeline by Promius Pharma, LLC, H2 2016
  • Psoriasis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Psoriasis - Pipeline by Prothena Corporation Plc, H2 2016
  • Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Psoriasis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Sandoz International GmbH, H2 2016
  • Psoriasis - Pipeline by Sareum Holdings Plc, H2 2016
  • Psoriasis - Pipeline by Selvita S.A., H2 2016
  • Psoriasis - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016
  • Psoriasis - Pipeline by Shulov Innovative Science Ltd., H2 2016
  • Psoriasis - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Psoriasis - Pipeline by Soligenix, Inc., H2 2016
  • Psoriasis - Pipeline by Spherium Biomed S.L., H2 2016
  • Psoriasis - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
  • Psoriasis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Psoriasis - Pipeline by SWITCH Biotech LLC, H2 2016
  • Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2016
  • Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Psoriasis - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016
  • Psoriasis - Pipeline by Telormedix SA, H2 2016
  • Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Psoriasis - Pipeline by TheraMAB LLC, H2 2016
  • Psoriasis - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Psoriasis - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Psoriasis - Pipeline by UCB S.A., H2 2016
  • Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
  • Psoriasis - Pipeline by Wellstat Therapeutics Corporation, H2 2016
  • Psoriasis - Pipeline by XBiotech Inc, H2 2016
  • Psoriasis - Pipeline by XenoPort, Inc., H2 2016
  • Psoriasis - Pipeline by Yuhan Corporation, H2 2016
  • Psoriasis - Pipeline by Ziarco Pharma Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Psoriasis - Dormant Projects, H2 2016
  • Psoriasis - Dormant Projects (Contd..1), H2 2016
  • Psoriasis - Dormant Projects (Contd..2), H2 2016
  • Psoriasis - Dormant Projects (Contd..3), H2 2016
  • Psoriasis - Dormant Projects (Contd..4), H2 2016
  • Psoriasis - Dormant Projects (Contd..5), H2 2016
  • Psoriasis - Dormant Projects (Contd..6), H2 2016
  • Psoriasis - Dormant Projects (Contd..7), H2 2016
  • Psoriasis - Dormant Projects (Contd..8), H2 2016
  • Psoriasis - Dormant Projects (Contd..9), H2 2016
  • Psoriasis - Dormant Projects (Contd..10), H2 2016
  • Psoriasis - Dormant Projects (Contd..11), H2 2016
  • Psoriasis - Dormant Projects (Contd..12), H2 2016
  • Psoriasis - Dormant Projects (Contd..13), H2 2016
  • Psoriasis - Dormant Projects (Contd..14), H2 2016
  • Psoriasis - Dormant Projects (Contd..15), H2 2016
  • Psoriasis - Dormant Projects (Contd..16), H2 2016
  • Psoriasis - Dormant Projects (Contd..17), H2 2016
  • Psoriasis - Dormant Projects (Contd..18), H2 2016
  • Psoriasis - Dormant Projects (Contd..19), H2 2016
  • Psoriasis - Dormant Projects (Contd..20), H2 2016
  • Psoriasis - Dormant Projects (Contd..21), H2 2016
  • Psoriasis - Dormant Projects (Contd..22), H2 2016
  • Psoriasis - Dormant Projects (Contd..23), H2 2016
  • Psoriasis - Dormant Projects (Contd..24), H2 2016
  • Psoriasis - Dormant Projects (Contd..25), H2 2016
  • Psoriasis - Dormant Projects (Contd..26), H2 2016
  • Psoriasis - Dormant Projects (Contd..27), H2 2016
  • Psoriasis - Discontinued Products, H2 2016
  • Psoriasis - Discontinued Products (Contd..1), H2 2016
  • Psoriasis - Discontinued Products (Contd..2), H2 2016
  • Psoriasis - Discontinued Products (Contd..3), H2 2016
  • Psoriasis - Discontinued Products (Contd..4), H2 2016
  • Psoriasis - Discontinued Products (Contd..5), H2 2016

List of Figures

  • Number of Products under Development for Psoriasis, H2 2016
  • Number of Products under Development for Psoriasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top